Date published: 2026-5-8

1-800-457-3801

SCBT Portrait Logo
Seach Input

LONRF1 Activators

LONRF1, also known as LON Peptidase N-Terminal Domain and Ring Finger 1, is an intricate protein that has a role in various cellular processes. It is a member of the Lon protease family, which are ATP-dependent proteases involved in the selective degradation of misfolded, damaged, or non-assembled proteins. The presence of a RING-finger domain, which is a characteristic feature of E3 ubiquitin ligases, suggests that LONRF1 may also participate in the ubiquitin-proteasome system, a critical pathway for protein degradation and regulation in the cell.The degradation of proteins by LONRF1 is essential for maintaining cellular homeostasis, particularly in the context of mitochondrial function and quality control. The proteolytic activity of LONRF1 is believed to be critical for the regulation of the mitochondrial proteome, helping to preserve the integrity of this organelle by removing damaged or unnecessary proteins. This activity is particularly important given the high susceptibility of mitochondrial proteins to oxidative damage due to the reactive oxygen species generated during electron transport and ATP synthesis.

LONRF1 may also be involved in the processing of proteins necessary for the proper assembly of mitochondrial complexes, which are crucial for oxidative phosphorylation. By selectively degrading certain protein substrates, LONRF1 ensures the optimal functioning of these complexes, thereby influencing cellular energy metabolism.In addition to its role in protein turnover, LONRF1's E3 ubiquitin ligase activity could implicate it in various signaling pathways, including those related to cell cycle control, apoptosis, and the response to cellular stress. Through ubiquitination, LONRF1 may tag specific proteins for degradation, thereby modulating their levels and activity within the cell.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

MG-132 [Z-Leu- Leu-Leu-CHO]

133407-82-6sc-201270
sc-201270A
sc-201270B
5 mg
25 mg
100 mg
$60.00
$265.00
$1000.00
163
(3)

A proteasome inhibitor, can affect ubiquitin-proteasome pathways, potentially influencing LONRF1 activity.

Lactacystin

133343-34-7sc-3575
sc-3575A
200 µg
1 mg
$188.00
$575.00
60
(2)

Another proteasome inhibitor, can modulate proteasome-mediated protein degradation, potentially impacting LONRF1.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$135.00
$1085.00
115
(2)

A selective proteasome inhibitor used in cancer therapy, might indirectly affect pathways involving LONRF1.

Epoxomicin

134381-21-8sc-201298C
sc-201298
sc-201298A
sc-201298B
50 µg
100 µg
250 µg
500 µg
$137.00
$219.00
$449.00
$506.00
19
(2)

A selective proteasome inhibitor, could impact proteasome function and thereby indirectly influence LONRF1.

Chloroquine

54-05-7sc-507304
250 mg
$69.00
2
(0)

Known to inhibit autophagy, can alter cellular protein degradation pathways, potentially affecting LONRF1.

Autophagy Inhibitor, 3-MA

5142-23-4sc-205596
sc-205596A
50 mg
500 mg
$65.00
$261.00
113
(3)

An autophagy inhibitor, might influence pathways related to protein turnover, potentially impacting LONRF1.

Leupeptin hemisulfate

103476-89-7sc-295358
sc-295358A
sc-295358D
sc-295358E
sc-295358B
sc-295358C
5 mg
25 mg
50 mg
100 mg
500 mg
10 mg
$73.00
$148.00
$316.00
$499.00
$1427.00
$101.00
19
(3)

An inhibitor of various proteases, including calpains and lysosomal proteases, potentially affecting LONRF1 activity.

PD 150606

179528-45-1sc-222133
sc-222133A
5 mg
25 mg
$118.00
$403.00
18
(1)

A specific calpain inhibitor, could indirectly influence proteolytic pathways relevant to LONRF1.